Pyxis Oncology (PYXS) Current Assets (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Current Assets data on file, last reported at $72.1 million in Q4 2025.

• Current Assets for Q4 2025 came in at $72.1 million, down 45.56% year-over-year; the trailing twelve-month figure through Dec 2025 was $72.1 million (down 45.56% YoY), and the FY2025 annual result was $72.1 million, down 45.56% from the prior year.
• Current Assets declined to $72.1 million in Q4 2025 per PYXS's latest filing, from $83.1 million in the prior quarter.
• Over five years, Current Assets peaked at $278.7 million in Q4 2021 and troughed at $72.1 million in Q4 2025.
• A 5-year average of $157.3 million and a median of $149.1 million in 2023 frame the typical range for Current Assets.
• The sharpest annual moves came in 2021 and 2025: Current Assets soared 3339.13% in 2021, then tumbled 45.56% in 2025.
• A 5-year view of Current Assets shows it stood at $278.7 million in 2021, then sank by 33.04% to $186.6 million in 2022, then sank by 33.23% to $124.6 million in 2023, then advanced by 6.29% to $132.4 million in 2024, then plunged by 45.56% to $72.1 million in 2025.
• Business Quant data shows PYXS's Current Assets at $72.1 million in Q4 2025, $83.1 million in Q3 2025, and $100.0 million in Q2 2025.